Follicular lymphoma develops when immune cells called B-cells acquire genetic errors that prevent them from dying on schedule, allowing them to accumulate in lymph nodes over years or decades. The median age at diagnosis is 64, and it affects men slightly more often than women, with incidence rates of 2.6 per 100,000 in males compared to 2.2 in females. Unlike many cancers, follicular lymphoma rarely has a single clear trigger. It results from a chain of genetic accidents, immune system dysfunction, and environmental exposures that build on each other over time.
The Core Genetic Error
The hallmark of follicular lymphoma is a specific chromosomal mix-up known as the t(14;18) translocation. During normal immune development, B-cells rearrange their DNA to produce antibodies. Occasionally, this process goes wrong, and a piece of chromosome 18 gets swapped onto chromosome 14. This places a gene called BCL2, which controls cell survival, next to a powerful switch that’s normally reserved for antibody production. The result: the BCL2 gene gets permanently turned on.
BCL2 is essentially an anti-death protein. It blocks the process cells normally use to self-destruct when they’re damaged or no longer needed. Under normal conditions, old or defective B-cells receive internal signals to shut down. When BCL2 is overproduced, those signals get ignored. The cells don’t necessarily multiply faster than normal, but they refuse to die, gradually piling up in lymph nodes and bone marrow.
Here’s what makes follicular lymphoma tricky to pin down: this translocation alone isn’t enough to cause cancer. Roughly half of all follicular lymphoma cases test positive for the classic version of this chromosomal swap, and studies have found the same translocation in the blood of healthy people who never develop lymphoma. Something additional has to go wrong.
Mutations That Reshape How Genes Are Read
Beyond the BCL2 translocation, follicular lymphoma cells carry a striking number of mutations in genes that control how DNA is packaged and read. These are called chromatin-modifying genes, and they don’t create new proteins or turn off tumor suppressors directly. Instead, they change which parts of the genome are accessible, subtly reprogramming the cell’s identity.
The most commonly mutated gene in follicular lymphoma is KMT2D, altered in roughly 72% of cases. Close behind is CREBBP, mutated in about 65% of cases. A gene called EZH2 is affected in 25% of cases, with several others (EP300, KMT2C, HIST1H1E, ARID1A) mutated at lower frequencies. About 70% of follicular lymphoma tumors carry mutations in two or more of these genes simultaneously. This layering of epigenetic errors helps explain why the disease develops slowly: each mutation nudges B-cells further from normal behavior without triggering the explosive growth seen in more aggressive cancers.
How the Immune System Accidentally Helps
Follicular lymphoma cells don’t survive in isolation. They depend heavily on the surrounding immune environment inside lymph nodes, and they’re remarkably good at manipulating it to their advantage.
Inside a tumor, a specific type of immune cell called follicular helper T-cells sends survival signals to the lymphoma cells, including a protein called IL-4 and a surface molecule called CD40L. In response, the lymphoma cells release chemical attractants (CCL17 and CCL22) that recruit regulatory T-cells to the area. These regulatory cells are the immune system’s peacekeepers. They suppress the activity of killer T-cells, natural killer cells, and other immune responders that would otherwise recognize and destroy the cancer. The result is a self-reinforcing loop: helper T-cells feed the lymphoma, the lymphoma recruits regulatory cells to suppress the immune response, and those regulatory cells create a safe zone where the cancer can grow undisturbed.
This dependency on the immune microenvironment is one reason follicular lymphoma behaves so differently from solid tumors. It also explains why the disease can sometimes wax and wane without treatment, because shifts in the local immune environment can temporarily slow or accelerate growth.
Autoimmune Conditions and Chronic Infection
Conditions that keep the immune system in a state of chronic activation can raise lymphoma risk. Sjögren’s syndrome, an autoimmune disorder that attacks moisture-producing glands, is one well-documented example. The constant stimulation of B-cells by the immune system creates more opportunities for genetic errors to accumulate. Chromosomal translocations combined with ongoing activation of survival pathways in B-cells can push cells toward malignancy over years of inflammation.
Chronic infections play a similar role. Hepatitis C virus, for instance, doesn’t just cause liver disease. It directly affects lymphocytes and drives the production of abnormal antibody complexes, sustaining B-cell activity in ways that increase the chance of cancerous transformation. Other infections linked to B-cell lymphomas in general include Helicobacter pylori and certain tick-borne bacteria, though these are more strongly associated with lymphomas arising in specific organs rather than the lymph nodes where follicular lymphoma typically develops.
Environmental and Chemical Exposures
Benzene, classified as a definite human carcinogen by the International Agency for Research on Cancer, has been studied extensively in relation to lymphoma. A large meta-analysis found that workers with high benzene exposure had a 51% increased risk of non-Hodgkin lymphoma compared to unexposed groups. For follicular lymphoma specifically, the data suggested a 47% increased risk in highly exposed individuals, though this finding did not reach statistical significance, meaning the connection is plausible but not yet proven beyond doubt.
For most people, benzene exposure comes not from industrial work but from everyday sources: car exhaust, gasoline fumes, and cigarette smoke. An estimated 50% of household benzene exposure among nonsmokers comes from secondhand smoke. Pesticides have also been investigated as potential risk factors, particularly among agricultural workers, though the evidence for follicular lymphoma specifically remains less clear-cut than for some other lymphoma subtypes.
Family History and Inherited Risk
Having a first-degree relative (parent, sibling, or child) with non-Hodgkin lymphoma raises your own risk by about 1.8-fold, according to a pooled analysis of over 17,000 lymphoma cases and 23,000 controls across 20 studies. That translates to a modest but real increase. The absolute risk remains low, since follicular lymphoma is uncommon to begin with, but the familial clustering points to inherited genetic variations that make some people’s B-cells more vulnerable to the mutations described above.
These inherited factors likely don’t cause lymphoma on their own. Instead, they may affect how efficiently someone’s cells repair DNA damage, how their immune system surveys for abnormal cells, or how readily the BCL2 translocation occurs during B-cell development. The interplay between inherited susceptibility and acquired mutations is why follicular lymphoma can run in families without following a predictable inheritance pattern.
What Doesn’t Appear to Cause It
Despite reasonable suspicion, obesity does not have a clear link to follicular lymphoma. A meta-analysis of prospective studies found no statistically significant association between body mass index and follicular lymphoma risk. Obese individuals had a relative risk of just 1.15, and statistical testing showed no meaningful trend between increasing weight and disease incidence. This stands in contrast to diffuse large B-cell lymphoma, where obesity does appear to play a role. The distinction reinforces that different types of lymphoma, even when they arise from the same cell type, have genuinely different causes.
When Follicular Lymphoma Transforms
In some patients, follicular lymphoma acquires additional genetic damage and transforms into diffuse large B-cell lymphoma, a faster-growing cancer that requires more aggressive treatment. This transformation happens through at least two distinct pathways. In one, cells acquire mutations in tumor-suppressing genes like TP53 (found in about 20% of transformed cases) or amplify cancer-promoting genes like c-MYC and c-REL. These changes dramatically increase the rate of cell division. In other cases, transformation occurs without a clear increase in proliferation, through mechanisms that remain poorly understood.
These transforming mutations are almost always acquired over time rather than present at diagnosis. They represent the next step in a progression that may have started decades earlier with a single chromosomal translocation in a developing B-cell. The slow, multi-step nature of this process is central to understanding follicular lymphoma: it is not caused by a single event but by the gradual accumulation of genetic and immune abnormalities, each one making the next more likely.